Prange Holding Gmbh

What Prange Holding Gmbh does

Prange Pharma GmbH is a privately held, family-owned pharmaceutical holding and operating company headquartered in Plettenberg, Germany, operating since 1996 as the pharmaceutical investment platform within the Prange Group. The company operates a diversified platform across three integrated business areas: Contract Development and Manufacturing Organization (CDMO) services through majority-owned Halden Pharma AS (Norway) and Aprilia Animal Health S.r.l. (Italy), plus minority interests in Adragos Pharma and Aenova Holding; human pharmaceutical product distribution via subsidiaries including Abanta Pharma (dermatology/urology), CARINOPHORM (hospital cardiology/intensive care), Vitane Pharma (operating in 25+ countries), GeneVida (generics), and GCT GmbH (dermocosmetics using proprietary OLT® technology); and animal health product distribution through PetVet GmbH (brands PHA®, LaPura®, 4-Beiner), Kauartikel.com (natural chew products, ~400 SKUs including AYKA brand), and Finest Meat GmbH.

Core CDMO capabilities include sterile manufacturing (large-volume parenterals up to 15,000-litre batch sizes, blow-fill-seal ampoules and vials), aseptic compounding with isolator technology, non-sterile liquids and gels (up to 5,300-litre batches, ATEX-compliant), and solid oral dosage forms. Manufacturing facilities are cGMP-certified and compliant with EU GMP, U.S. FDA, and other international regulatory requirements. The digital health layer, built primarily through minority investments, includes AI-supported platforms: Curio Digital Therapeutics (women's mental health), LipoCheck (lipedema diagnostic tools), and Prio One (telemedicine).

The business model combines professional services revenue from CDMO contracts with transaction-based revenue from pharmaceutical and animal health distribution across multiple channels — direct hospital and pharmacy sales, pharmaceutical wholesalers, e-commerce (own stores and Amazon), and international export partners. Customer segments span pharmaceutical companies requiring contract manufacturing, healthcare providers (hospitals, pharmacies), animal health retailers and pet owners, and patients using digital therapeutics. The platform employs more than 1,000 people across at least six countries with more than 60 nationalities, reflecting its diversified international footprint and family-controlled long-term investment approach.

Name

Prange Holding Gmbh

Legal name

Prange Pharma GmbH

Website

https://prange-pharma.de

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Prange Pharma GmbH is a family-owned German pharmaceutical platform operating CDMO manufacturing (sterile and non-sterile production) through facilities in Norway and Italy, human pharma distribution across Europe, and animal health product sales, serving hospitals, pharmacies, wholesalers, and consumers in 6+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical contract manufacturing
• CDMO services
• Animal health products
• Pharmaceutical distribution
• Digital health therapeutics

Headquarters

HQ city

Plettenberg

HQ country

Germany

HQ region

Europe

Offices18 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Services: Contract development and manufacturing services for pharmaceutical companies, including technology transfer, validation, analytical services, commercial manufacturing, packaging, and QP release. Revenue generated from manufacturing fees, development services, and regulatory support.
2. Human Pharmaceuticals Distribution: Marketing and distribution of prescription drugs, OTC products, medical devices, and dermocosmetics through pharmacies, hospitals, and pharmaceutical wholesalers. Includes portfolio companies like Abanta Pharma (urology, dermatology) and Carinopharm (cardiology, intensive care).
3. Animal Health Products Distribution: Distribution of dietary supplements, grooming products, and natural chew toys for dogs, cats, and horses through own online stores, Amazon, pharmacies, and wholesalers. Own brands include PHA®, LaPura®, 4-Beiner, AYKA.
4. Digital Health Solutions: Digital therapeutics and health platforms including Curio (women's health), LipoCheck (lipedema), Prio One (telemedicine), and others, generating revenue through app-based services and partnerships.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels4 records

Core offering

Prange Pharma GmbH operates as the pharmaceutical investment and operating platform of the family-owned Prange Group, delivering contract development and manufacturing (CDMO) services for human and veterinary pharmaceuticals through owned facilities in Norway (Halden Pharma AS) and Italy (Aprilia Animal Health S.r.l.), plus minority stakes in Adragos Pharma and Aenova. The company distributes established human pharmaceuticals (prescription, OTC, medical devices, dermocosmetics) through portfolio companies such as Abanta Pharma (urology/dermatology) and Carinopharm (hospital cardiology/intensive care), and sells animal health products including dietary supplements, grooming products, and natural chew toys under brands PHA®, LaPura®, 4-Beiner, and AYKA.

Product overview

Prange Pharma operates as a diversified pharmaceutical platform with three integrated business areas: (1) Contract Development and Manufacturing (CDMO) through Halden Pharma AS (Norway) and Aprilia Animal Health S.r.l. (Italy), plus minority stakes in Adragos Pharma GmbH and Aenova Holding GmbH, providing sterile and non-sterile manufacturing services for human and veterinary pharmaceuticals; (2) Human Medicines Product Distribution through portfolio companies including Abanta Pharma (dermatology/urology), CARINOPHARM (cardiology/hospital sector), digital health companies (Curio Digital Therapeutics, LipoCheck, Prio One), and international pharmaceutical distributors (Vitane Pharma, GeneVida, GCT, Uropharm); and (3) Animal Health Product Sales through PetVet GmbH (brands: PHA®, LaPura®, 4-Beiner) and Kauartikel.com (natural chew products with brand AYKA). The company combines pharmaceutical manufacturing with product distribution and digital health solutions.

Differentiator

Problem solved

Functional benefit

Brands

• Abanta: Distribution of prescription and OTC pharmaceuticals, medical devices, and cosmetics with focus on dermatology and urology
• CARINOPHARM
• Curio Digital Therapeutics
• LipoCheck
• Prio One
• Vitane Pharma
• Fenou
• GCT
• GeneVida
• THUSTMED
• Uropharm
• PetVet
• Kauartikel.com
• Finest Meat
• Halden Pharma
• Aprilia Animal Health
• Adragos Pharma
• Aenova

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, minor and growth.

• Halden Pharma AScoreStrategic or Co-development PartnerMajority-owned CDMO manufacturing facility in Norway specializing in sterile manufacturing (LVP & SVP) with capabilities including large-volume infusion solutions (50-5,000 ml), blow-fill-seal, terminal sterilisation, and batch sizes up to 15,000 litres. Also handles non-sterile liquids and gels with ATEX-compliant production.
• Aprilia Animal Health S.r.l.coreStrategic or Co-development PartnerMajority-owned CDMO facility in Italy for human and veterinary pharmaceuticals. Capabilities include sterile forms (suspensions, solutions, powders), non-sterile forms (solutions, ointments, powders, sprays), and various packaging formats.
• Adragos Pharma GmbHminorStrategic or Co-development PartnerMinority interest in Munich-based CDMO offering sterile production (fill & finish), lyophilization, and non-sterile formulations with technology transfer, analytics, and clinical manufacturing services.
• Aenova Holding GmbHminorStrategic or Co-development PartnerMinority interest in full-service CDMO with development and production across all common dosage forms (solid, semisolid, liquid; sterile and non-sterile). Broad technology portfolio including tablets, capsules, sterile vials, lyophilized products, and pre-filled syringes.
• Carinopharm GmbHcoreStrategic or Co-development PartnerShareholder in specialty pharmaceutical company specializing in cardiology, intensive care, and emergency medicine for the German hospital sector. Also operates in Italy with highest quality standards.
• Abanta Pharma GmbHcoreStrategic or Co-development PartnerSubsidiary marketing established pharmaceutical products in the German market with focus on urology and dermatology. Combines extensive market experience with strong relationships throughout the German healthcare system.
• Curio Digital Therapeutics, Inc.growthStrategic or Co-development PartnerMinority investment in US-based company developing AI-powered digital therapeutics for women's health, focusing on mental health including postpartum depression with clinically validated treatment programs.
• LipoCheck GmbHgrowthStrategic or Co-development PartnerMinority investment in digital lipedema platform providing patient-centered networking, AI-supported diagnostic tools, and therapy support throughout the care pathway.
• Prio One, Healthtech Ventures GmbHgrowthStrategic or Co-development PartnerMinority investment in telemedicine platform for women's health covering contraception, weight management, and other gynecological areas with discreet medication delivery.
• Vitane Pharma GmbHgrowthChannel Partner/ Reseller/ DistributorMinority investment in healthcare company with international presence in 25+ countries focusing on dietary supplements, medical devices, and pharmaceuticals with customer-centric support.
• HP Inc.minorOthersFDA Agent service provider for internal and external clients handling all administrative tasks for US market access.
• INCA-Pharm S.r.l.minorOthersItalian company serving as FDA Agent for all administrative tasks supporting market access in the United States.

Scale indicators7 records

Direct peers

• Dechra Pharmaceuticals: Specialty animal health pharmaceutical company developing and marketing veterinary medicines. Comparable to Prange's animal health business through PetVet and Aprilia Animal Health in veterinary pharma focus and distribution model.
• Recipharm AB: Swedish CDMO offering contract development and manufacturing of pharmaceuticals in multiple dosage forms. Recipharm is a European mid-tier CDMO directly comparable in scale and therapeutic breadth to Prange Pharma's manufacturing subsidiaries.
• Siegfried Holding AG: Swiss-listed CDMO with full API and finished dosage form manufacturing across sterile and non-sterile formats. Siegfried is one of the closest publicly traded comparables to Prange's Halden Pharma and Aprilia Animal Health operations in scale and European footprint.
• Phoenix Group: European pharmaceutical wholesale and distribution leader headquartered in Germany. Comparable to Prange's distribution arm (Abanta, Carinopharm, Vitane) for European pharma wholesaling across prescription, OTC, and specialty therapeutics.
• Aenova Holding GmbH: Full-service CDMO offering development and production across all common dosage forms (sterile and non-sterile). Prange holds a minority interest in Aenova, making it both a directly comparable CDMO peer and a related-party operator in the same European CDMO landscape.
• Fareva: Privately held French CDMO with manufacturing facilities across Europe and globally for sterile, liquid, semi-solid, and solid dosage forms. Direct CDMO peer with similar family-owned, multi-site European profile.
• NextPharma: European CDMO offering development, manufacturing, and packaging services across solid, semi-solid, liquid, and sterile formats. Comparable to Prange in serving small-to-mid-sized pharma customers with multi-format manufacturing capabilities.
• Adragos Pharma GmbH: Munich-based CDMO specializing in sterile production, aseptic filling, lyophilization, and non-sterile formulations. Like Aenova, Adragos is a Prange minority interest and a directly comparable European CDMO peer with overlapping technology capabilities.

Broad incumbents

• Lonza Group AG: Swiss-listed global CDMO with leading position in biologics, cell and gene therapy, and small molecule manufacturing. Lonza operates at substantially larger scale than Prange but competes for the same large-volume, complex-molecule contracts that Halden Pharma targets.
• Catalent, Inc. Global CDMO leader offering softgel, oral, sterile, and biologics manufacturing at scale. Catalent is a broad incumbent in the same CDMO space as Prange, though at materially larger scale and broader geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/invita-pharma-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries25 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prange Holding Gmbh